• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

1,142
109
75
71
68

COUNTRY

70
22
16
10
9

CATEGORIES

  • 574
  • 119
  • 550
  • 75
  • 526
  • 43
  • 505
  • 18
  • 18
  • 23

PRICE

1,017
1,203
1,832
2,986

PUBLISHED

16
207
648
2,986

PRODUCT TYPE

2,412
494
70
7
1
1
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE
Colorectal Cancer - KOL Insight Module Colorectal Cancer - KOL Insight Module - Product Thumbnail Image

Colorectal Cancer - KOL Insight Module

The global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift due to wider generic competition in cytotoxics and increasing adoption of anti-EGFR products as first line therapies...

October 2013
FROM

Europe Breast Cancer Drug Pipeline Analysis

The pharmaceutical companies have recently been focusing increasingly on women's health Among the diseases specific to women, breast cancer has become one of the leading causes of death for the women...

October 2013
FROM

Orphan Drugs for Cancer Pipeline Analysis

A huge market opportunity is offered by small patient population which suffers from rare or orphan diseases Among the category of new orphan drugs, Oncology account for the largest disease group in...

October 2013
FROM

US Breast Cancer Drug Pipeline Analysis

The pharmaceutical companies have recently been focusing increasingly on women's health Among the diseases specific to women, breast cancer has become one of the leading causes of death for the women...

October 2013
FROM

US Prostate Cancer Drug Pipeline Analysis

Prostate cancer has emerged as one of the most commonly diagnosed cancer among men in the US According to the American Cancer Society, there were close to 242,000 new cases of prostate cancer in the...

October 2013
FROM

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies

Solid Tumors Market in Asia Pacific to 2019 - New Drug Approvals and Anticipated Product Launches to Trigger a Shift in Treatment Paradigm to Targeted Therapies Summary The leading business intelligence...

September 2013
FROM

Osteosarcoma Global Clinical Trials Review, H2, 2013

Osteosarcoma Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Osteosarcoma Global Clinical Trials Review, H2, 2013" provides data on the Osteosarcoma clinical trial scenario....

September 2013
FROM

Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H2, 2013

Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H2, 2013 Summary Our clinical trial report, “Chemotherapy Induced Nausea and Vomiting Global Clinical Trials Review, H2, 2013"...

September 2013
FROM
Genomic Biomarkers for Pharmaceutical Development Genomic Biomarkers for Pharmaceutical Development - Product Thumbnail Image

Genomic Biomarkers for Pharmaceutical Development

Genomic Biomarkers for Pharmaceutical Development: Advancing Personalized Health Care provides an in-depth review of the state of translational science across all stages of pharmaceutical development...

September 2013

Non-Small Cell Lung Carcinoma - Pipeline Review, H2 2013

Non-Small Cell Lung Carcinoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Non-Small Cell Lung Carcinoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

September 2013
FROM

Nonhematologic Malignancy - Pipeline Review, H2 2013

Nonhematologic Malignancy - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Nonhematologic Malignancy - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

September 2013
FROM

B-Cell Lymphomas - Pipeline Review, H2 2013

B-Cell Lymphomas - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'B-Cell Lymphomas - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

September 2013
FROM

Multiple Myeloma (Kahler's Disease) - Pipeline Review, H2 2013

Multiple Myeloma (Kahler's Disease) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Multiple Myeloma (Kahler's Disease) - Pipeline Review, H2 2013', provides an overview of the indication’s...

September 2013
FROM

Metastatic Melanoma - Pipeline Review, H2 2013

Global Markets Direct's, 'Metastatic Melanoma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline This report provides information on the therapeutic development...

September 2013
FROM

Peritoneal Tumor - Pipeline Review, H2 2013

Peritoneal Tumor - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Peritoneal Tumor - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

September 2013
FROM

Relapsed Multiple Myeloma - Pipeline Review, H2 2013

Relapsed Multiple Myeloma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Relapsed Multiple Myeloma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline....

September 2013
FROM

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013

Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Glioblastoma Multiforme (GBM) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

September 2013
FROM

Metastatic Cancer - Pipeline Review, H2 2013

Metastatic Cancer - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Metastatic Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

September 2013
FROM

Chemotherapy Induced Anemia - Pipeline Review, H2 2013

Chemotherapy Induced Anemia - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Chemotherapy Induced Anemia - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic...

September 2013
FROM

Colon Carcinoma - Pipeline Review, H2 2013

Colon Carcinoma - Pipeline Review, H2 2013 Summary Global Markets Direct’s, 'Colon Carcinoma - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report...

September 2013
FROM
Loading Indicator

Our Clients

Our clients' logos